Maker Of Opioid Addiction Implant Withholds Initial Public Offering

Braeburn Pharmaceuticals Inc., makers of the first U.S. long-acting implant to treat opioid addiction have decided to withhold initial public offering (IPO) due to current market uncertainty. The company had filed to go public in late December, 2016. The company is currently undecided about considering a future IPO.

Braeburn Pharmaceuticals is a commercial-stage pharmaceutical company offering medicinal treatment options for serious central nervous system disorders, and is active in investigational treatments for serious neurological and behavioral health disorders.

This was reported by Reuters on February 2, 2017.

Contact Information: Braeburn Pharmaceuticals Inc., 47 Hulfish . . .